| Fund Raise Amount | ₹300 CrApproved Limit |
|---|---|
| Market Cap | ₹372.3 CrSmall Cap |
| Revenue TTM | ₹156 CrAnnual Operating |
| MFI | 85.06Overbought Zone |
| Deal value | ₹300 Cr |
| Share of market cap | 80.6% |
Key highlights
- Board approved raising up to ₹300 Crore via private placement of convertible and non-convertible instruments
- Funding instruments include Compulsorily Convertible Debentures (CCDs), CCPS, and Non-Convertible Debentures (NCDs)
- Mandate issued to acquire USFDA, EU-GMP, or WHO/GMP compliant pharmaceutical manufacturing units in India
- Whole-time Director Sudheer Karna Kankanala authorized to lead acquisition negotiations and evaluations
- CFO Balayogiswara Rao Peddinti to manage discussions with prospective investors and financial institutions
What Is the Fund Raise?
The Board of Directors has authorized a capital raise of up to ₹300 Crore through a private placement of various securities to prospective investors and financial institutions. This planned infusion will utilize a combination of convertible instruments, such as Compulsorily Convertible Debentures (CCDs) and Compulsorily Convertible Preference Shares (CCPS), alongside Non-Convertible Debentures (NCDs). Chief Financial Officer Balayogiswara Rao Peddinti is tasked with leading the negotiations to secure these funding sources.
The initiative remains subject to necessary statutory, regulatory, and shareholder approvals as part of the company's broader capital restructuring efforts.
Use of Proceeds
- Evaluating and negotiating the acquisition of pharmaceutical manufacturing units located within India
- Targeting facilities that already possess USFDA, EU-GMP, or WHO/GMP certifications and approvals
- Expanding existing manufacturing capacity to accommodate rising global order volumes
- Strengthening the company's operational presence and competitive standing in international markets
- Deploying capital to integrate high-compliance assets into the company's evolving pharmaceutical portfolio
Strategic Rationale
The decision to raise ₹300 crore—nearly 80% of the company's current market capitalization—signals an aggressive pivot into high-standard pharmaceutical manufacturing. By focusing on brownfield acquisitions of USFDA and EU-GMP compliant units, Astal Laboratories aims to bypass the extensive lead times required for greenfield regulatory audits. Whole-time Director Sudheer Karna Kankanala is spearheading this search to ensure new assets meet the stringent quality benchmarks required for export markets.
This strategy is designed to immediately enhance production throughput and allow the company to capture a larger share of the global generic drug supply chain.
Business Overview & Financial Context
Astal Laboratories Limited, formerly known as Macro International Limited, is transitioning from its traditional roots in commodity trading toward a specialized pharmaceutical focus. The company currently reports a trailing twelve-month revenue of ₹156 crore, with a recent quarterly revenue growth of 74.36% year-on-year. Despite a low promoter holding of 4.53%, the stock has shown significant momentum, recently trading with a Money Flow Index (MFI) of 85.06, indicating strong buying interest.
This capital raise represents a foundational shift to scale the balance sheet and support the company's new identity as a compliance-focused manufacturer.
| Share price | ₹88.19 |
|---|---|
| Market capitalisation | ₹372.30 Cr |
| Revenue (annual) | ₹156.00 Cr |
| Net profit (annual) | ₹8.12 Cr |
| Revenue (latest quarter) | ₹40.92 Cr-21.67% vs previous quarter |
| Net profit (latest quarter) | ₹1.09 Cr-53.93% vs previous quarter |
| P/E (TTM) | 45.88×Sector 36.86× |
| Promoter holding | 4.53%-13.66% QoQ |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Astal Laboratories Limited announcing the outcome of the Board Meeting regarding fund raising and acquisition mandates. Market figures from a third-party data provider.
